BPC-157

Overview

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a partial sequence derived from a larger protective protein identified in human gastric juice, and it was characterised through the 1990s by a research group led by Predrag Sikirić at the University of Zagreb School of Medicine. The name is shorthand for 'Body Protection Compound', reflecting the original hypothesis that a stable fragment of this gastric protein might account for the mucosa's remarkable capacity for self-repair even in the presence of continuous acid exposure.

Unlike many peptides discussed on this site, which were designed rationally from first principles or isolated from glandular extracts, BPC-157 was engineered as a stable, synthesisable fragment of a naturally occurring protective molecule. The Zagreb programme's stated rationale was that if a short, chemically robust sequence from within the parent protein retained its biological activity, it could be manufactured reproducibly and studied systematically across organ systems well beyond the stomach. Over three decades this is broadly what happened: the compound has been examined in models of tendon and ligament injury, gastric and duodenal ulceration, colitis and other bowel pathology, skin and burn wounds, spinal cord and peripheral nerve injury, and vascular occlusion.

The scope of the preclinical literature on BPC-157 is unusually broad for an unlicensed research peptide, with well over 100 published studies from the Zagreb group and a growing number of independent laboratories internationally. Reported effects span accelerated tendon-to-bone healing, protection of gastric and intestinal mucosa against a wide range of experimental insults, promotion of blood-vessel growth into damaged tissue, and modulation of the nitric oxide system. This breadth is part of what has made BPC-157 a subject of considerable interest — and also part of why it attracts scepticism, since a single short peptide claimed to influence such a wide range of tissue types warrants particularly careful scrutiny of the evidence base.

Public interest in BPC-157 has grown considerably faster than the underlying clinical evidence base, driven substantially by anecdotal use within strength-sport and recreational-athletics communities rather than by any expansion of the human trial record. This gap between popular enthusiasm and the actual state of clinical evidence is worth naming directly, because it is the single most common source of confusion for readers encountering BPC-157 for the first time: the rodent literature is genuinely extensive and, in the tendon and gut domains, methodologically reasonable by preclinical standards, but it has not been followed by the controlled human studies that would normally be expected before a compound is considered for any therapeutic application.

Part of BPC-157's prominence also owes to its position at the intersection of sports-medicine, orthopaedic and gastroenterology research interest, three fields that rarely converge on the same molecule. Orthopaedic researchers have been drawn to the tendon and ligament literature given how poorly these tissues heal under conventional care, gastroenterology researchers to the mucosal-protection literature given the scale of peptic ulcer and NSAID-induced gut injury as clinical problems, and vascular researchers to the angiogenesis data given its relevance to ischaemic tissue more broadly. This cross-disciplinary interest has not, however, translated into a coordinated clinical development programme of the kind seen with clinical-stage peptides, and BPC-157 remains a compound studied almost exclusively in academic preclinical settings rather than within an industry-sponsored drug-development pathway.

This page summarises the preclinical mechanism-of-action literature, the research history of the compound, the safety data reported in animal studies, and the regulatory position in the United Kingdom. Nothing on this page is medical advice, and BPC-157 is not a licensed medicine anywhere in the world. As with the other compounds catalogued on this site, the material presented here is intended for laboratory and research audiences, and the translational gap between an extensive rodent literature and an almost complete absence of registered human trials should be treated as the central caveat running through everything that follows.

Mechanism of action

The most frequently cited mechanism for BPC-157 in the angiogenesis literature is upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) signalling. In cultured endothelial cells and in tendon-explant models, BPC-157 exposure has been reported to increase VEGFR2 expression and downstream phosphorylation of its associated signalling intermediates, promoting endothelial cell migration and tube formation consistent with new blood-vessel growth. Because tendon and ligament tissue is characteristically hypovascular and heals slowly for that reason, the proposed route by which BPC-157 accelerates tendon repair in rodent models is largely attributed to this pro-angiogenic action, allowing nutrient and growth-factor delivery to reach an otherwise poorly perfused healing site. Some in vitro work has additionally reported increased expression of early-response angiogenic transcription factors following BPC-157 exposure in endothelial cell lines, which the original authors present as upstream of the VEGFR2 effect, although the full signalling cascade from peptide binding to receptor upregulation has not been resolved to the level of detail expected for a validated molecular target.

A second, closely related mechanism concerns the nitric oxide (NO) system. Several Zagreb-group papers report that BPC-157's cytoprotective and healing-promoting effects in the gut and in vascular models can be blocked by co-administration of NO-synthase inhibitors such as L-NAME, and restored by co-administration of the NO precursor L-arginine. This has led to the proposal that BPC-157 acts, at least in part, by modulating the L-arginine-nitric oxide pathway, normalising NO production in tissue beds where it is either deficient (impairing healing) or in excess (contributing to inflammatory injury). The bidirectional nature of this reported effect — correcting NO levels whether they are too high or too low relative to the healthy baseline — is one of the more distinctive and debated claims in the mechanistic literature. This proposed 'normalising' rather than uniformly stimulating action on NO synthesis is also invoked to explain reported effects on blood pressure and vascular tone in some rodent hypertension and portal-hypertension models, where BPC-157 administration has been reported to counteract both pathologically elevated and pathologically suppressed vascular responses depending on the experimental model, a pattern that is mechanistically interesting but methodologically difficult to verify without independent replication using standardised NO-flux assays.

A third proposed mechanism involves interaction with growth-hormone receptor signalling and the growth-hormone/IGF-1 axis in the context of tendon fibroblast activity. In vitro work on tendon-derived fibroblasts has reported that BPC-157 exposure increases growth-hormone receptor expression and enhances the migratory response of fibroblasts to growth-hormone stimulation, which in combination with the angiogenic effect described above is proposed as the basis for BPC-157's most consistently reported preclinical effect: accelerated healing at the tendon-to-bone (enthesis) junction, a notoriously slow-healing interface in both animal models and human orthopaedic practice. Related rodent work on ligament and muscle-crush injury has reported similar patterns of accelerated functional recovery, measured variously by tensile-strength testing of the healing tissue, treadmill or grip-strength performance, and histological scoring of collagen organisation at the repair site, with the enthesis and myotendinous-junction literature generally regarded as the most methodologically consistent subset of the wider BPC-157 dataset.

In the gastrointestinal tract, where the compound's activity was first characterised, BPC-157 has been reported to stabilise gastric and intestinal mucosal integrity across a wide range of experimentally induced injuries, including ethanol- and NSAID-induced ulceration, and surgically induced fistulae. Proposed mechanisms here include the angiogenic and NO-pathway effects described above, together with reported modulation of prostaglandin pathways, preservation of mucosal blood flow under injurious conditions, and effects on the enteric nervous system relevant to gut motility. Collectively these mechanisms are best understood as overlapping and mutually reinforcing rather than as a single validated pathway, and it should be noted that much of the mechanistic dissection has been performed by the originating research group rather than replicated independently at the molecular level. A further reported effect within this tissue compartment concerns anastomotic and fistula healing following experimental gut surgery, where BPC-157 has been described as improving healing at surgical join sites and reducing leak rates in rodent models, an application the original authors link back to the same combination of angiogenic and mucosal-protective mechanisms rather than to any distinct additional pathway.

Research history

The BPC-157 research programme originates with Predrag Sikirić and colleagues at the University of Zagreb School of Medicine, with the compound's protective properties in gastric models first characterised in the early 1990s. The stated starting point was the observation that gastric juice itself contains factors that protect and repair the stomach lining even during continuous acid exposure, and the Zagreb team set out to isolate a stable, synthesisable peptide fragment responsible for this activity.

From that gastric starting point, the programme expanded steadily outward across three decades to examine tendon, ligament, muscle, skin, bone, spinal cord, peripheral nerve, corneal and vascular tissue, in addition to continued work on stomach, oesophagus, colon and liver models. Rodent and, to a lesser extent, other animal models form the overwhelming majority of this literature, with the tendon-and-ligament healing studies and the gastrointestinal protection studies representing the two most substantial and most frequently cited bodies of work. Review articles by members of the original group, including a widely cited 2014 review by Sikirić and colleagues, attempt to synthesise this cross-organ activity into a unified 'cytoprotection' framework.

Through the 2010s the compound also began to attract attention from research groups outside Zagreb, particularly in Taiwan and other centres examining tendon fibroblast biology, and more recently from laboratories investigating hind-limb ischaemia and vascular recovery. This broadening of the author base beyond the originating group is a meaningful development for the credibility of the mechanistic claims, even though the total volume of independently authored work remains small relative to the Zagreb-group corpus, and even though independent groups have generally examined narrower mechanistic questions rather than reproducing the full breadth of organ-system claims made in the earlier literature.

It is important to state plainly what this research history does not include: there is, to date, no completed and published randomised controlled trial of BPC-157 in humans, despite a preclinical literature exceeding 100 published studies. The compound has not progressed through the standard translational pathway of dose-ranging phase I safety studies followed by controlled efficacy trials that would ordinarily bridge such an extensive animal literature to clinical use. This translational gap — a large body of largely single-group preclinical data without a corresponding human trial record — is the central limitation to bear in mind when assessing claims made about BPC-157, and it is one of the reasons the compound remains firmly in the research-chemical category rather than any stage of licensed drug development.

Summarised studies